# Kentaro Igarashi

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 114 papers | 2,068 citations | 26 h-index | 38 g-index |
| 115 ext. papers | 2,304 ext. citations | 4 avg, IF | 4.5 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 114 | Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Oncotarget*, **2016**, 7, 47556-47564 | 3.3 | 87 |
| 113 | High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. *Oncotarget*, **2016**, 7, 33046-54 | 3.3 | 86 |
| 112 | Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. *Oncotarget*, **2016**, 7, 85929-85936 | 3.3 | 74 |
| 111 | Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. *Oncotarget*, **2016**, 7, 71737-71743 | 3.3 | 71 |
| 110 | Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Oncotarget*, **2017**, 8, 35630-35638 | 3.3 | 68 |
| 109 | Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. *Oncotarget*, **2017**, 8, 85516-85525 | 3.3 | 56 |
| 108 | Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. *Journal of Cellular Biochemistry*, **2017**, 118, 2314-2319 | 4.7 | 52 |
| 107 | Risk factors of recurrent lumbar disk herniation: a single center study and review of the literature. *Journal of Spinal Disorders and Techniques*, **2015**, 28, E265-9 | | 52 |
| 106 | Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. *Cancer Letters*, **2018**, 417, 168-173 | 9.9 | 47 |
| 105 | Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. *Cell Cycle*, **2017**, 16, 1164-1170 | 4.7 | 45 |
| 104 | Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. *Oncotarget*, **2017**, 8, 8035-8042 | 3.3 | 44 |
| 103 | A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. *Oncotarget*, **2017**, 8, 62111-62119 | 3.3 | 42 |
| 102 | Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. *Cell Cycle*, **2018**, 17, 801-809 | 4.7 | 41 |
| 101 | Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. *Cancer Letters*, **2018**, 432, 251-259 | 9.9 | 41 |
| 100 | Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. *Cell Cycle*, **2017**, 16, 91-94 | 4.7 | 37 |
| 99 | The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. *Cell Cycle*, **2017**, 16, 1046-1052 | 4.7 | 35 |
| 98 | High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. *Journal of Cellular Biochemistry*, **2017**, 118, 2739-2743 | 4.7 | 34 |

| | | | |
|---|---|---|---|
| 97 | Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. *Cell Cycle*, **2017**, 16, 1288-1294 | 4.7 | 34 |
| 96 | Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. *Oncotarget*, **2018**, 9, 915-923 | 3.3 | 34 |
| 95 | Therapeutic Targets for Bone and Soft-Tissue Sarcomas. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 34 |
| 94 | Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. *Cell Cycle*, **2018**, 17, 356-361 | 4.7 | 33 |
| 93 | Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Oncotarget*, **2017**, 8, 75874-75880 | 3.3 | 32 |
| 92 | The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and deletion: Direction for third-line patient therapy. *Oncotarget*, **2017**, 8, 103129-103136 | 3.3 | 32 |
| 91 | Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model. *Anticancer Research*, **2018**, 38, 5639-5644 | 2.2 | 32 |
| 90 | MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). *Oncotarget*, **2017**, 8, 47490-47496 | 3.3 | 31 |
| 89 | Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. *Journal of Cellular Biochemistry*, **2017**, 118, 361-365 | 4.7 | 30 |
| 88 | Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. *Cell Cycle*, **2017**, 16, 1063-1069 | 4.7 | 26 |
| 87 | Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. *Journal of Cellular Biochemistry*, **2018**, 119, 3537-3544 | 4.7 | 26 |
| 86 | Pedicle versus free frozen autograft for reconstruction in malignant bone and soft tissue tumors of the lower extremities. *Journal of Orthopaedic Science*, **2014**, 19, 156-63 | 1.6 | 24 |
| 85 | Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft. *PLoS ONE*, **2013**, 8, e71362 | 3.7 | 24 |
| 84 | A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX). *Oncotarget*, **2017**, 8, 63353-63359 | 3.3 | 24 |
| 83 | Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. *Oncotarget*, **2018**, 9, 11119-11125 | 3.3 | 23 |
| 82 | Joint-preservation surgery for pediatric osteosarcoma of the knee joint. *Cancer and Metastasis Reviews*, **2019**, 38, 709-722 | 9.6 | 23 |
| 81 | Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. *Biochemical and Biophysical Research Communications*, **2018**, 497, 1055-1061 | 3.4 | 22 |
| 80 | Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review. *Cells*, **2019**, 8, | 7.9 | 21 |

| | | | |
|---|---|---|---|
| 79 | Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model. *Biochemical and Biophysical Research Communications*, **2019**, 513, 326-331 | 3.4 | 21 |
| 78 | Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. *Oncotarget*, **2018**, 9, 19263-19272 | 3.3 | 19 |
| 77 | Pioglitazone, an agonist of PPAR reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression. *Biomedicine and Pharmacotherapy*, **2019**, 118, 109356 | 7.5 | 18 |
| 76 | Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. *Biochemical and Biophysical Research Communications*, **2018**, 503, 3086-3092 | 3.4 | 18 |
| 75 | Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. *Biochemical and Biophysical Research Communications*, **2018**, 506, 912-917 | 3.4 | 17 |
| 74 | Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. *Cell Cycle*, **2018**, 17, 868-873 | 4.7 | 16 |
| 73 | Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma. *Anticancer Research*, **2019**, 39, 4653-4657 | 2.3 | 16 |
| 72 | Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. *Tissue and Cell*, **2018**, 53, 30-36 | 2.7 | 15 |
| 71 | Efficacy of glycogen synthase kinase-3 targeting against osteosarcoma via activation of catenin. *Oncotarget*, **2016**, 7, 77038-77051 | 3.3 | 15 |
| 70 | Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. *Oncotarget*, **2018**, 9, 7774-7781 | 3.3 | 15 |
| 69 | Glycogen synthase kinase 3 as a potential therapeutic target in synovial sarcoma and fibrosarcoma. *Cancer Science*, **2020**, 111, 429-440 | 6.9 | 14 |
| 68 | Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel. *Anticancer Research*, **2017**, 37, 61-65 | 2.3 | 14 |
| 67 | The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. *Cancer Chemotherapy and Pharmacology*, **2020**, 85, 285-291 | 3.5 | 14 |
| 66 | A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. *Biochemical and Biophysical Research Communications*, **2018**, 505, 733-739 | 3.4 | 14 |
| 65 | Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. *Cell Cycle*, **2018**, 17, 627-633 | 4.7 | 13 |
| 64 | Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy. *Journal of Cellular Biochemistry*, **2018**, 119, 6598-6603 | 4.7 | 13 |
| 63 | Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. *BMC Cancer*, **2018**, 18, 840 | 4.8 | 13 |
| 62 | Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. *Cancer Medicine*, **2015**, 4, 333-41 | 4.8 | 13 |

| | | | |
|---|---|---|---|
| 61 | TNF-□and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors. *PLoS ONE*, **2012**, 7, e52926 | 3.7 | 13 |
| 60 | Prognostic value of radiological response to chemotherapy in patients with osteosarcoma. *PLoS ONE*, **2013**, 8, e70015 | 3.7 | 13 |
| 59 | MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. *Tissue and Cell*, **2018**, 52, 124-128 | 2.7 | 13 |
| 58 | Analysis of Stroma Labeling During Multiple Passage of a Sarcoma Imageable Patient-Derived Orthotopic Xenograft (iPDOX) in Red Fluorescent Protein Transgenic Nude Mice. *Journal of Cellular Biochemistry*, **2017**, 118, 3367-3371 | 4.7 | 12 |
| 57 | Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model. *Anticancer Research*, **2019**, 39, 4781-4786 | 2.3 | 12 |
| 56 | Eribulin regresses a doxorubicin-resistant Ewing□s sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model. *Journal of Cellular Biochemistry*, **2018**, 119, 967-972 | 4.7 | 12 |
| 55 | A novel combined radiological method for evaluation of the response to chemotherapy for primary bone sarcoma. *Journal of Surgical Oncology*, **2012**, 106, 273-9 | 2.8 | 12 |
| 54 | A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. *Pharmacological Research*, **2019**, 142, 169-175 | 10.2 | 12 |
| 53 | Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model. *Anticancer Research*, **2019**, 39, 4079-4084 | 2.3 | 11 |
| 52 | Effective Metabolic Targeting of Human Osteosarcoma Cells and in Orthotopic Nude-mouse Models with Recombinant Methioninase. *Anticancer Research*, **2017**, 37, 4807-4812 | 2.3 | 11 |
| 51 | Patient-derived orthotopic xenograft models of sarcoma. *Cancer Letters*, **2020**, 469, 332-339 | 9.9 | 11 |
| 50 | Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. *Cancer Letters*, **2019**, 451, 122-127 | 9.9 | 10 |
| 49 | Effectiveness of two novel anionic and cationic platinum complexes in the treatment of osteosarcoma. *Anti-Cancer Agents in Medicinal Chemistry*, **2015**, 15, 390-9 | 2.2 | 10 |
| 48 | The outcomes of reconstruction using frozen autograft combined with iodine-coated implants for malignant bone tumors: compared with non-coated implants. *Japanese Journal of Clinical Oncology*, **2016**, 46, 735-40 | 2.8 | 10 |
| 47 | Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. *Cell Cycle*, **2018**, 17, 2019-2026 | 4.7 | 10 |
| 46 | Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. *Cancers*, **2020**, 12, | 6.6 | 9 |
| 45 | Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. *Cell Cycle*, **2018**, 17, 722-727 | 4.7 | 9 |
| 44 | Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. *Journal of Drug Targeting*, **2019**, 27, 211-216 | 5.4 | 9 |

| | | | |
|---|---|---|---|
| 43 | Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. *Anticancer Research*, **2019**, 39, 4775-4779 | 2.3 | 9 |
| 42 | High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models. *Oncotarget*, **2017**, 8, 19065-19073 | 3.3 | 9 |
| 41 | PPAR□Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model. *Cancer Genomics and Proteomics*, **2020**, 17, 35-40 | 3.3 | 9 |
| 40 | Tumor-targeting A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. *Heliyon*, **2018**, 4, e00643 | 3.6 | 8 |
| 39 | Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. *Translational Oncology*, **2019**, 12, 640-645 | 4.9 | 8 |
| 38 | The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Biomedicine and Pharmacotherapy*, **2019**, 111, 835-840 | 7.5 | 8 |
| 37 | The usefulness of wide excision assisted by a computer navigation system and reconstruction using a frozen bone autograft for malignant acetabular bone tumors: a report of two cases. *BMC Cancer*, **2018**, 18, 1036 | 4.8 | 8 |
| 36 | Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model. *Archives of Gynecology and Obstetrics*, **2019**, 299, 1683-1690 | 2.5 | 7 |
| 35 | The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model. *Translational Oncology*, **2019**, 12, 1257-1263 | 4.9 | 7 |
| 34 | Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice. *Anticancer Research*, **2017**, 37, 1005-1011 | 2.3 | 7 |
| 33 | The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model. *Cancer Chemotherapy and Pharmacology*, **2019**, 83, 1075-1082 | 3.5 | 6 |
| 32 | Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. *Biochemical and Biophysical Research Communications*, **2020**, 523, 135-139 | 3.4 | 6 |
| 31 | Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. *JCO Precision Oncology*, **2017**, 2017, | 3.6 | 5 |
| 30 | Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting A1-R is superior to first-line chemotherapy. *Signal Transduction and Targeted Therapy*, **2018**, 3, 12 | 21 | 5 |
| 29 | Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models. *Anticancer Research*, **2016**, 36, 4477-82 | 2.3 | 5 |
| 28 | Calcium Phosphate Cement in the Surgical Management of Benign Bone Tumors. *Anticancer Research*, **2018**, 38, 3031-3035 | 2.3 | 5 |
| 27 | High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer. *Methods in Molecular Biology*, **2019**, 1866, 149-161 | 1.4 | 4 |
| 26 | A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. *Cancer Genomics and Proteomics*, **2020**, 17, 217-223 | 3.3 | 4 |

| | | | |
|---|---|---|---|
| 25 | Exquisite Tumor Targeting by Salmonella A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model. *Translational Oncology*, **2020**, 13, 393-400 | 4.9 | 4 |
| 24 | Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. *Anticancer Research*, **2017**, 37, 4081-4084 | 2.3 | 4 |
| 23 | The process of bone regeneration from devitalization to revitalization after pedicle freezing with immunohistochemical and histological examination in rabbits. *Cryobiology*, **2020**, 92, 130-137 | 2.7 | 4 |
| 22 | Secondary Osteoarthritis After Curettage and Calcium Phosphate Cementing for Giant-Cell Tumor of Bone Around the Knee Joint: Long-Term Follow-up. *JBJS Open Access*, **2020**, 5, | 3.1 | 4 |
| 21 | Clinical course of grafted cartilage in osteoarticular frozen autografts for reconstruction after resection of malignant bone and soft-tissue tumor involving an epiphysis. *Journal of Bone Oncology*, **2020**, 24, 100310 | 4.5 | 4 |
| 20 | Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer. *Cancer Genomics and Proteomics*, **2021**, 18, 113-120 | 3.3 | 4 |
| 19 | Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. *Journal of Cellular Biochemistry*, **2018**, 119, 7827-7833 | 4.7 | 4 |
| 18 | Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. *Tissue and Cell*, **2019**, 58, 107-111 | 2.7 | 3 |
| 17 | Recombinant Methioninase Combined With Tumor-targeting A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma. *Anticancer Research*, **2020**, 40, 2515-2523 | 2.3 | 3 |
| 16 | Real-Time In Vivo Confocal Fluorescence Imaging of Prostate Cancer Bone-Marrow Micrometastasis Development at the Cellular Level in Nude Mice. *Journal of Cellular Biochemistry*, **2016**, 117, 2533-7 | 4.7 | 3 |
| 15 | Late recurrence of osteosarcoma: a report of two cases. *Journal of Orthopaedic Surgery*, **2014**, 22, 415-9 | 1.4 | 3 |
| 14 | Accuracy of histological grades from intraoperative frozen-section diagnoses of soft-tissue tumors. *International Journal of Clinical Oncology*, **2020**, 25, 2158-2165 | 4.2 | 3 |
| 13 | The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma. *Scientific Reports*, **2021**, 11, 1989 | 4.9 | 2 |
| 12 | Reconstruction using a frozen autograft for a skull and humeral lesion of synchronous multicentric osteosarcoma after undergoing successful neoadjuvant chemotherapy: a case report and review of the literature. *BMC Surgery*, **2021**, 21, 56 | 2.3 | 2 |
| 11 | Determining Patient Satisfaction and Treatment Desires in Patients With Musculoskeletal Sarcoma of the Knee After Joint-preservation Surgery Using a Questionnaire Survey. *Anticancer Research*, **2019**, 39, 1965-1969 | 2.3 | 1 |
| 10 | Methioninase Cell-Cycle Trap Cancer Chemotherapy. *Methods in Molecular Biology*, **2019**, 1866, 133-148 | 1.4 | 1 |
| 9 | Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. *Cancer Genomics and Proteomics*, **2020**, 17, 351-358 | 3.3 | 1 |
| 8 | Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors. *Anticancer Research*, **2018**, 38, 4065-4072 | 2.3 | 1 |

| | | | |
|---|---|---|---|
| 7 | Cystic extraskeletal osteosarcoma: Three case reports and review of the literature. *Molecular and Clinical Oncology*, **2020**, 12, 468-474 | 1.6 | 1 |
| 6 | Risk Factors for Postoperative Deep Infection After Malignant Bone Tumor Surgery of the Extremities. *Anticancer Research*, **2020**, 40, 3551-3557 | 2.3 | 1 |
| 5 | Clinical outcomes of frozen autograft reconstruction for the treatment of primary bone sarcoma in adolescents and young adults. *Scientific Reports*, **2021**, 11, 17291 | 4.9 | 1 |
| 4 | Distal Tibial Tuberosity Focal Dome Osteotomy Combined With Intra-Articular Condylar Osteotomy (Focal Dome Condylar Osteotomy) for Medial Osteoarthritis of the Knee Joint. *Arthroscopy Techniques*, **2020**, 9, e1079-e1086 | 1.7 | 0 |
| 3 | Precision medicine for recalcitrant cancers with the patient-derived orthotopic xenograft (PDOX) mouse models for identification of effective therapy.. *Journal of Clinical Oncology*, **2017**, 35, e23164-e23164 | 2.2 | |
| 2 | Long-term survival in a patient with Hutchinson-Gilford progeria syndrome and osteosarcoma: A case report. *World Journal of Clinical Cases*, **2021**, 9, 854-863 | 1.6 | |
| 1 | Primary total knee arthroplasty assisted by computed tomography-free navigation for secondary knee osteoarthritis following massive calcium phosphate cement packing for distal femoral giant-cell bone tumor treatment: a case report.. *BMC Musculoskeletal Disorders*, **2022**, 23, 170 | 2.8 | |